The startup Macromo, founded by the trio Eva Kuttichová, Petr Štěpánek and Michal Pohludka, uses machine learning, statistics and a custom-made artificial intelligence model to give everyone a clear and complete overview of their health risks. It would help people protect their health and allow their doctors to make more informed decisions before their clients develop visible symptoms of a disease. All based on DNA analysis.
“With Macromo, Tomáš Čupr’s group is coming with powerful technology that can not only process huge amounts of data, but is also starting to be able to interpret it,” TCF Capital said on its LinkedIn profile. What particularly appealed to Čupr’s investment company was the use of technology in diagnostics and interpretation of genetic test results.
“This investment round is not just financing – it is a strategic partnership with TCF Capital, which truly understands what we are building. TCF Capital, founded by Tomáš Čupr, brings valuable experience and credibility to the partnership thanks to its key asset – the Rohlik group, whose value exceeds a billion dollars,” said Macromo co-founder Eva Kuttichová. She did not specify how much of a stake TCF Capital acquired in Macromo or how much it has invested in the company and will eventually invest.
Macromo started four years ago with the sale of home genetic tests. “But gradually we understood something deeper: To truly understand your health, you need all your health data. Today, you can upload any laboratory result to our application – even competitive DNA tests or blood tests,” Kuttichová describes.
